Di Marco Roberto, Mangano Katia, Quattrocchi Cinzia, Musumeci Rosario, Speciale Anna Maria, Papaccio Gianpaolo, Buschard Karsten, Bendtzen Klaus, Nicoletti Ferdinando
Department of Microbiological and Gynaecological Sciences, University of Catania, Catania, Italy.
Clin Immunol. 2003 Dec;109(3):266-71. doi: 10.1016/s1521-6616(03)00213-4.
Fusidic acid and sodium fusidate (fusidin) are antibiotics with low toxicity and powerful immunomodulatory activities in vitro and in vivo. In this study we have evaluated the effect of fusidin on the development of dinitrobenzenesulfonic acid (DNB)-induced colitis in rats that serves as a preclinical model of human inflammatory bowel disease (IBD). The data show that when administered orally at the dose of 80 (but not 40) mg/kg body wt under a "therapeutic" regimen soon after DNB application, fusidin significantly ameliorates clinical, histological, and seroimmunological signs of disease. These entailed a significant reduction in body weight loss, smaller increase in colon weights, milder macroscopic damage, and lower histological scores. In addition, when sacrificed at the end of the study, fusidin-treated rats had significantly lower blood levels of tumor necrosis factor alpha and interferon-gamma compared with untreated controls. The present findings concur with the beneficial actions of fusidin in a pilot study conducted in patients with Crohn's disease and warrant controlled studies in humans with IBD.
夫西地酸和夫西地酸钠（梭链孢酸钠）是一类抗生素，在体外和体内均具有低毒性和强大的免疫调节活性。在本研究中，我们评估了夫西地酸钠对二硝基苯磺酸（DNB）诱导的大鼠结肠炎发展的影响，该大鼠结肠炎模型可作为人类炎症性肠病（IBD）的临床前模型。数据显示，在DNB给药后不久，按照“治疗”方案以80（而非40）mg/kg体重的剂量口服给药时，夫西地酸钠可显著改善疾病的临床、组织学和血清免疫学症状。这些症状包括体重减轻显著减少、结肠重量增加较小、宏观损伤较轻以及组织学评分较低。此外，在研究结束时处死大鼠时，与未治疗的对照组相比，接受夫西地酸钠治疗的大鼠血液中肿瘤坏死因子α和干扰素-γ的水平显著降低。本研究结果与在克罗恩病患者中进行的一项初步研究所发现的夫西地酸钠的有益作用一致，并且有必要对IBD患者进行对照研究。
